Metformin use associated with reduced risk of frailty in diabetes patients

• A total of 422 patients aged more than 40 years with a history of type 2 diabetes.
• The data was collected related to general information and exposure (metformin)
• The assessments and laboratory investigations were performed.
• The follow-up period was 4.5 years.
• The primary outcomes measured were the combined endpoint of cardiovascular and cerebrovascular events, readmission, and death.
• Binary logistic regression analysis (to analyze association) and Survival analysis were used.
• The total prevalence of frailty was 19.4%.
• In the metformin and non-metformin groups, 13.1% and 28.2% respectively had frailty.

Metformin was inversely associated with frailty after adjustments (age, sex, duration, blood glucose levels, comorbidities, and polypharmacy).

In the non-frail group, metformin decreased the risk of combined primary outcomes.

To conclude, Metformin use causes reduced risk of frailty.

Frailty may attenuate metformin’s protective effects, so early identification and prevention of frailty progression enhance the metformin benefits in diabetic patients.

Further reading:

Liu, P. et al. Association of metformin exposure with low risks of frailty and adverse outcomes in patients with diabetes. Eur J Med Res 28, 65 (2023). https://doi.org/10.1186/s40001-023-01017-6